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Polyketide products are useful compounds to research and industry but can be 
difficult to access due to their richness in stereogenic centers. Type I polyketide synthases 
offer unique engineering opportunities to access natural stereocontrol and resultant 
complex compounds. The development of a controlled in vitro platform based around 
type I polyketide synthases is described. It has been used to produce a small library of 
polyketide fragments on an unprecedented and synthetically-relevant scale and explore 
polyketide synthase enzymology. 
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POLYKETIDES AND THEIR SYNTHASES 
Polyketides are structurally diverse secondary metabolites whose broad utility has 
generated intense interest in their production. Type I polyketide synthases (PKSs) have 
their many catalytically independent enzymes fused into multidomain assembly-line 
stations, called modules. At each module, a defined set of chemical reactions is 
performed before passing the product of that module to the next module. Modules and 
enzymes within a module cooperate in series to synthesize diverse molecules, often rich 
in stereogenic centers (Weissman 2009). In this way, the arrangement of domains with 
the gene cluster controls the content and layout of the synthase and thus the structure of 
the product (Hertweck 2009; Cane 2010). The metabolic cost entailed in encoding and 
producing these very long lines of enzymes must be justified by evolutionary advantages 
for the organisms that produce them. In addition to the direct advantage of a compound 
produced by any specific type I PKS, the modular configuration of these biosynthetic 
gene clusters confers the advantage of rapid evolution of new compounds. This is 
because they are amenable to duplication, insertion, deletion, and rearrangement to 
produce new compounds in a way that non-modular biosynthetic clusters are not 
(Fischbach et al. 2008).  
Polyketide synthases in this project generally assemble their complex scaffolds 
from simple propionyl groups to begin the assembly line and a methylmalonyl group to 
extend the product at each module. The domains relevant to this thesis include the 
ketosynthase (KS), the acyltransferase (AT), the acyl carrier protein (ACP), the 
ketoreductase (KR), and the thioesterase (TE).  
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Figure 1. Select steps in polyketide biosynthesis. 
The steps of polyketide biosynthesis most relevant to this project are (figure 1, Adapted 
from Cane 2010):  
1. the KS is acylated by an upstream ACP 
2. the AT attaches a methylmalonyl group to the ACP as a thioester 
3. the KS catalyzes a decarboxylative condensation to extend the product, leaving it 
attached to the ACP as a β-keto-thioester 
4. the KR may at this point reduce the β-keto group, simultaneously setting 
stereochemical configuration of α- and β-carbons. The product shown here is B2-
type (Keatinge-Clay 2007). 
5. (not shown) this process may be repeated by downstream modules until the 
resultant scaffold reaches a terminal TE which releases is from the ACP. 
There are two different ways in which type I PKS gene clusters are valuable to the 
goal of broadening access to untapped biochemical abilities. Firstly, they code for the 
ability to manufacture a huge number of pre-evolved, bioactive small molecules. 
Polyketides and their derivatives have been repeatedly reappropriated from toxins into 
powerful and successful agents in pharmacy, agriculture, and biotechnology based on 
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their antibacterial, antifungal, anticancer, insecticide, and other bioactive properties. 
Secondly, type I PKS gene clusters arrange all the reactions necessary to polyketides in a 
customizable configuration. This could provide access to customized polyketide products 
as well as natural ones. It has long been a goal of investigators to use polyketide 
synthases to access new polyketides, designed to order, by engineering their synthases 
(Weissman and Leadlay 2005). 
CHALLENGES IN ACCESSING POLYKETIDE PRODUCTS 
Access to a library of thousands of pre-evolved, presumably bioactive compounds 
is a worthwhile goal. The most direct access route would be to simply purify these 
polyketides from organisms that are already producing them. Progress along this route 
has been frustrated by the cryptic origins of many polyketides, the often limited 
feasibility of culturing the organism once it is discovered, and the notoriously low titers 
of the desired compounds produced in culture.  
The most well studied polyketide producing system is certainly the erythromycin 
synthase (Khosla et al. 2007). However, even within this model system, fundamental 
concepts such as interactions within the synthase (Kapur et al. 2010; Kapur et al. 2012) or 
rational routes to in vivo overproduction (Lum et al. 2004; Peano et al. 2012) are only 
beginning to be understood. Given this status quo in the model system of type I PKSs, 
simultaneously overcoming all the same hurdles in thousands of polyketide producing 
organisms is not currently a practical approach. Current heterologous PKS production 
technologies in E. coli also suffer from similarly impractical yields and so offer no 
immediate help (Zhang et al. 2010). 
Chemical synthesis offers an organism-independent route to utilizing polyketide 
products. But while these complex total syntheses offer enriching challenges to synthetic 
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chemists, their large scale syntheses often prove challenging and can preclude the 
development of even the most promising compounds (Wender et al. 2011).  
THE IMPORTANCE OF CHIRAL BUILDING BLOCKS 
 
Figure 2. The use of chiral intermediates in a large-scale discodermolide total synthesis. 
The large-scale synthesis of discodermolide (Figure 2, excerpted from Mickel et 
al. 2004) demonstrates the remarkable utility of chiral intermediates in the synthesis of 
complex polyketide targets. However, the chiral pool of such intermediates is usually 
limited to sugars, amino acids, and Roche esters (Hilterhaus and Liese 2007) which are 
not always suitable. Polyketide fragments or molecules resembling them would be more 
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relevant. In addition to usefulness as chiral precursors in the synthesis of natural 
polyketides, such polyketide fragments would be rich in stereogenic sp
3
 carbons and 
therefore desirable for building new molecules with these qualities, which are more likely 
to be specific protein binders (Clemons et al. 2010). 
Simultaneously inspired by the challenges in synthesizing complex polyketide-
related molecules, and the stereocontrol and accessibility of polyketide synthases as 
catalysts, we set about to assemble an in vitro polyketide biosynthetic platform. We did 
this simultaneously produce chiral intermediates for more complex syntheses and to 
better understand basic questions about these remarkable catalysts. 
THE CURRENT STATE OF IN VITRO POLYKETIDE SYNTHESIS 
Structural exploration has increased insight into PKS function at the domain level 
(Khosla et al. 2007) but many questions about mechanisms and interactions within the 
context of a modular or multimodular system remain unanswered. Dissecting the 
immense complexity of these so-called “megasynthases” is certainly no small task, but in 
vitro experiments have also faced frustrating limitations leading many studies to explore 
questions amenable to in vivo strategies. 
One of these limitations is the complex biological cofactors used by these 
synthases. Their simple carbon extender units are delivered in vivo as CoA thioesters, 
which are difficult to access synthetically and costly to purify. This is reflected in their 
commercial price. Methylmalonyl-CoA, for example, is available from Sigma Aldrich for 
approximately $75 per milligram. A 
14
C-labelled version is also available, but its cost is 
not publicly available. Likewise the reducing power of polyketide synthases is supplied 
by the complex cofactor NADPH, which costs several dollars per milligram and is 
generally used stoichiometrically. 
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This limited accessibility of substrates leads investigators to make in vitro PKS 
experiments extremely small scale and necessarily reliant on detection methods sensitive 
to micrograms to nanograms of product (Kapur et al. 2010; Kapur et al. 2012). These 
high-sensitivity methods are generally low-throughput and do not provide rigorous 
characterization of products. 
The largest exception in the field is the common use of N-acetyl-cysteamine 
(NAC) thioesters as a truncated mimics of upstream acyl-ACPs in acylating the active 
sites of KS domains (Kinoshita et al. 2003; Lee et al. 2011; Zhang et al. 2010). However, 
it is not common practice to use a NAC thioester to acylate the active site of an AT 
domain as a truncated CoA mimic. While one AT has been shown to accept extender 
units linked to NAC instead of CoA (i.e. methylmalonyl-S-NAC instead of 
methylmalonyl-S-CoA) (Pohl et al. 1998), these NAC-based extender units are not 
commercially available, and the practice has not yet been commonly adopted. 
PREVIOUS IN VITRO PKS ACCOMPLISHMENTS OF THE KEATINGE-CLAY GROUP 
 During an attempt to use the Streptomyces coelicolor malonyl-CoA ligase 
(MatB) to generate methylmalonyl-CoA in vitro, Hughes and Keatinge-Clay (2011) 
discovered that this promiscuous enzyme could generate a not only methylmalonyl-CoA 
but also methylmalonyl-pantetheine and methylmalonyl-S-NAC. Moreover, this NAC-
based extender unit was used by the terminal module and thioesterase of the 
erythromycin synthase (EryMod6TE) to extend a diketide-S-NAC to produce an achiral 
triketide pyrone. It was also demonstrated that EryMod6TE can produce a variety of 
achiral triketide pyrones by both extending a variety of non-natural β-keto-diketides 
(Figure 3) and perform two extensions on monoketide NAC thioesters using NAC-based 
extender units (Hughes et al. 2012). 
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Figure 3. Select pyrones generated by Hughes et al. 2012. 
The Keatinge-Clay group was simultaneously investigating KR domains, already 
shown to be active outside the context of their modules (Siskos et al. 2005). Piasecki et 
al. (2011) found that a variety of isolated KRs were highly active and exert stereocontrol 
on diketide-S-NAC substrate analogues while reducing them from β-ketoacyl-S-NACs to 
chiral β-hydroxyacyl-S-NACs. Additionally, it was shown that NADPH can be supplied 
to these KRs by regenerating it thousands of times from NADP
+
 using glucose and 
Bacillus subtilis glucose dehydrogenase (GDH) (Piasecki et al. 2011). This approach 
drove ketoreduction towards completion, resulting in no measurable residual substrate. 
Not only could the reactions be initiated with the more economical NADP
+
, the ratio for 
cofactor concentration was no longer stoichiometric, making KR biocatalysis far more 
practical. The concentration of NADP
+
 was simply maintained at the minimal 
concentration sufficient for completion of the reactions. In scaling up these reactions to 
higher concentrations, Piasecki et al. (2011) also demonstrated the utility of dialyzed cell 
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lysate in place of purified enzyme. In these reactions, dialyzed lysate is equally effective 
but less time- and resource-intensive to produce than purified enzyme. 
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Results and Discussion 
MODIFICATION OF MATB AND KR REACTIONS 
 In order to create synthetically-meaningful quantities of polyketide 
fragments in vitro, MatB reactions were concentrated 20-fold, from 5mM to 100mM, to 
make the most use of the enzyme. The buffering power was also increased and initial pH 
of the reactions raised to compensate for the release of pyrophosphoric acid during the 
reaction. Reactions were carried out on the gram scale (5.00 mmol, 1.17 g theoretical 
yield). Accessibility of MatB products was also greatly increased by locating an 
economical source of ATP (Meiya Pharmaceuticals $0.20/g) which is generated by an 
enzymatic method, rather than purifying from an organism. 
The KR reactions were likewise concentrated to 100mM and buffer 
concentrations raised to compensate for the release of gluconic acid. A variety of β-keto-
diketide-S-NACs known to be extended by EryMod6TE (Hughes at al. 2012) were 
selected to be reduced to β-hydroxy-diketide-S-NAC by a suitable ketoreductase 
(Piasecki et al. 2011). In this way, chiral diketide-S-NACs 5-7 (Figure 4) were produced 
in separate reactions up to the gram scale. 
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Figure 4. Scheme for in vitro polyketide biosynthesis. 
GENERATION OF TRIKETIDE LACTONES BY ERYMOD6TE 
EryMod6TE had been shown to produce a chiral triketide lactone containing four 
contiguous stereocenters (8) in vitro, although only in trace quantities (Castonguay et al. 
2007; Chen et al. 2007; Oliynyk et al. 1996; Wiesmann et al. 1995). However, 
unprecedented amounts of triketide lactones 8 and 11 were generated when dialyzed 
lysate containing EryMod6TE was supplemented with diketide-S-NAC 5 and 
methylmalonyl-S-NAC (1) from KR and MatB reactions, respectively (Table 1). 
Additionally, EryMod6TE promiscuity allowed precursor-directed control of substituents 
at the R1 and R2 positions allowing the generation new lactones 9 and 10, as well as their 
ketolactones 12 and 13. Continued action of the NADPH-regeneration system from the 
KR reactions allowed the KR of EryMod6TE (EryKR6) to reduce the β-ketoacyl-ACP 
intermediates to produce reduced triketide lactones 8-10. If reduced diketides 5-7 were 
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separated from the NADPH-regeneration system by ethyl acetate (EtOAc) extraction 




















3 0.5 + 9 7.3 9 
3 0.5 - 12 5.6 7 
4 0.5 + 10 8.4 10 
4 0.5 - 13 3.4 4 







Table 1. Biocatalytic syntheses of triketide lactones 
It is significant that the ketolactone 11 was the major product of the reaction 
generating the reduced lactone 8. Both compounds result from extension of diketide 5 
and so share a common α,γ-dimethyl-β-ketoacyl-ACP intermediate which was a more 
often acted upon by the TE than by the KR. Intermediates resulting from the extension of 
6 and 7 were γ-unsubstituted and more often acted upon by the KR than by the TE as 
ketolactones 12 and 13 were only generated in trace quantities in the presence of 
NADPH. This previously undocumented substrate preference of EryKR6 in the model 
erythromycin PKS demonstrates the ability of this cell-free system to measure relative 
rates of competing reactions within a module. 
The multimilligram amounts triketides produced allowed for new levels of 




H NMR and MS. A 
small-molecule crystal structure of 11 was solved by Constance Bailey using triketide 
lactone produced in vitro (Figure 5). 
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Figure 5. Analytical advantages of in vitro PKS biocatalysis on an unprecedented scale. 
A) Stacked plot of an HPLC time course (λ=242 nm) of an EryMod6TE reaction 
measuring both reactants (1 and 5) and main product (11). Some timepoints have been 
omitted for readability. B) A plot of relative peak area (arbitrary units) versus time, 
following the same reaction. C) A crystal structure of 11 in its enol tautomer (crystal 
structure details available in Harper et al. 2012).  
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Monitoring progress of ketolactone-forming reactions with HPLC 
Although the β-ketoesters of ketolactones 11-13 are weak chromophores 
(λmax=248 nm), they were made in concentrations sufficient to track their formation by 
HPLC and photodiode array detector. Because β-hydroxyacyl-S-NACs and 
methylmalonyl-S-NAC are also UV active (λmax=233 nm and λmax=235 nm, respectively), 
all reactants and the desired product could be tracked through the course of reactions 
generating 11 (Figure 6), 12 (Figure 7), and 13 (Figure 8). Peak areas of all these species 
were charted through the course of 24 h reactions to better display the relative rate of 
their formation (Figure 9) 
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Figure 6. Stacked plot of an HPLC time course (λ=242 nm) of an EryMod6TE reaction 
generating 11 over 24 h. 
A complete version of the abbreviated time course appearing in figure 5A. The decrease 
of methylmalonyl-S-NAC 1 and (2S,3R)-3-hydroxy-2-methylpentanoyl-S-NAC 5 as well 
as formation of 11 can be followed over the course of the reaction. 
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Figure 7. Stacked plot of an HPLC time course (λ=242 nm) of an EryMod6TE reaction 
generating 12 over 24 h. 
The decrease of methylmalonyl-S-NAC 1 and (3R)-3-hydroxy-pentanoyl-S-NAC 6 as 
well as formation of 12 can be followed over the course of the reaction. 
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Figure 8. Stacked plot of an HPLC time course (λ=242 nm) of an EryMod6TE reaction 
generating 13 over 24 h. 
The decrease of methylmalonyl-S-NAC 1 and (3R)-3-hydroxy-hexanoyl-S-NAC 7 and 




Figure 9. Triplicate time courses of all three ketolactone-producing reactions. 
Plots of HPLC peak area (arbitrary units) over reaction time (hours). In each plot, the 
extender unit methylmalonyl-S-NAC 1 is in red, the reduced diketide S-NAC is in green, 
and the triketide ketolactone is in blue. Reactions were done in triplicate. A) Extension 
and cyclization of 5 by EryMod6TE to form 11. B) Extension and cyclization of 6 by 
EryMod6TE to form 12. C) Extension and cyclization of 7 by EryMod6TE to form 13. 
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ERYMOD6TE STEREOCHEMICAL SUBSTRATE SELECTIVITY 
The ability to track relevant chemical species through the course of ketolactone 
formation and the ability to generate not only 5, but also its three stereoisomers 
(Piasecki et al. 2011) was used to explore the stereoselectivity of EryMod6TE. An 
isolated KR from each class was chosen based on its activity against NAC-based 
substrates: AmpKR2 for A1-type product, RifKR7 for A2-type product, TylKR1 
for B1-Type product, and EryKR1 for B2-type product (Figure 10). EryMod6TE 
demonstrated strict selectivity for the B2-type product. This is not unprecedented 
among ModTEs, 5 and its stereoisomers could all acylate the KS of EryMod2TE, 
but again only the B2-type 5 was extended (Wu et al. 2004). EryMod2 acts on a 
B2-type product. It is surprising that EryMod6TE only extends B2-type products 
because in the synthesis of erythromycin it extends an A1-type product, which 
possesses the opposite stereochemistry at the α- and β-carbons,. It is possible that 
the substrate selectivity of EryKS6 is altered outside the context of the synthase or 
against NAC-based substrates (rather than its natural ACP-based substrate). It is 
also possible that this stereoselectivity is enforced by EryTE.  
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Figure 10. Triplicate HPLC time courses testing the stereocontrol of EryMod6TE. 
Plots of HPLC peak area (arbitrary units) over reaction time (hours) showing the 
reactants and desired product of ketolactone formation by EryMod6TE from 5 and its 
three stereoisomers. A) (2S,3R)-3-hydroxy-2-methylpentanoyl-S-NAC, generated by 
incubating 2 with AmpKR2 (A1-type), yielded trace quantities of ketolactone. This is 
consistent with the formation of the trace quantities of 5 as a side product of the reduction 
of 2 by AmpKR2 (Piasecki et al. 2011). B) (2R,3R)-3-hydroxy-2-methylpentanoyl-S-
NAC, generated by incubating 2 with RifKR7 (A2-type), did not yield ketolactone. C) 
(2R,3R)-3-hydroxy-2-methylpentanoyl-S-NAC, generated by incubating 2 with TylKR1 
(B1-type), did not yield ketolactone. D) (2S,3R)-3-hydroxy-2-methylpentanoyl-S-NAC 





ADDITIONAL TERMINAL MODTES 
Module TE Selection, partial cloning, and expression of two constructs 
In an effort to access more triketide lactone stereochemistries and determine the 
nature of EryMod6TE’s stereocontrol, more ModTEs were selected for cloning and 
expression. To avoid possible disruptions in module activity resulting from non-natural 
TE fusions, terminal modules with genes that included TEs were chosen. These included 
the terminal modules from the amphotericin synthase (AmpMod18TE), the oleandomycin 
synthase (OleMod6TE), the pikromycin synthase (PikMod6TE), the spinosad synthase 
(SpnMod10TE), and the tylosin synthase (TylMod7TE). Primers (Table 4) were designed 
with the assistance of Dr. Jianting Zheng, who also provided genomic DNA. 
All modules were amplified from their genomic DNA. PikMod6TE and 
SpnMod10TE were successfully ligated into an expression vector. After it was 
demonstrated by SDS-PAGE that these modules were expressed, preliminary chemical 
characterization took precedent over integrating the remaining modules in vectors. 
Detection of TE-mediated glycerolysis activity by fluorescent HPLC 
The Keatinge-Clay group has developed a fluorescent-HPLC method to measure 
in vitro PKS activity more sensitively and detect more chemical species. This is done by 
acylating the KS with a terminal-alkynyl-S-NAC, allowing the reaction to proceed, 
attaching an azide derivative of sulforhodamine using the azide-alkyne Huisgen 
cycloaddition, and then analysis using HPLC and a fluorometer (Hughes and Keatinge-
Clay, 2013 manuscript in preparation). 
During the course of this work it was demonstrated that EryTE uses a primary 
alcohol from a buffer glycerol molecule in place of water to result in glycerolysis, rather 
than hydrolysis, of terminal-alkynyl-S-NACs. Both Pik6TE and Spn10TE generated the 
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peak that Hughes and Keatinge-Clay assigned to glycerolysis product at approximately 
the same order of magnitude as EryMod6TE. This activity was observed with 4-
pentynoyl-S-NAC and 6-heptynoyl-S-NAC. This suggests that both constructs are well 
folded and that the TEs of both are catalytically active. This glycerolysis product has not 
been confirmed by MS or NMR. PikMod6TE and SpnMod10TE have not been further 
explored using this method. 
Stereochemical substrate selectivity of PikMod6TE and SpnMod10TE 
The same technique used to map EryMod6TE’s stereochemical requirement for 
diketide extension was applied to PikMod6TE and SpnMod10TE in hopes of accessing 
new ketolactones. SpnMod10TE was supplied with malonyl-S-NAC as it uses a malonyl-
group (rather than a methylmalonyl group) in the context of its synthase. Both modules 
were supplied with 5 and its stereoisomers, as well as pantetheine-thioesters of the same 
diketides. Ketolactone formation by SpnMod10TE was not observed.  
PikMod6TE was observed to extend A1-type diketides (as pantetheine and NAC 
thioesters) as well as B2-type diketides. Compared to the EryMod6TE control, 
PikMod6TE is more active against A1-type substrates, producing the A1- and B2-type 
ketolactones at ~40 % and ~20 % of the level at which EryMod6TE generates B2-type 
ketolactone. Because lysate was used, catalyst concentration was not controlled. This 
means that these measurements reflect catalyst concentration as well as catalytic rate. The 




The immediate next step should be NMR confirmation of A1-type triketide 
ketolactone and measurement of its specific rotation to compare with that of its 
enantiomer (11). 
Now that the lab’s fluorescent HPLC assay is out of preliminary stages, its use to 
further interrogate SpnMod10TE and PikMod6TE is appealing, especially since only TE 
activity has been observed from SpnMod10TE. It would also immediately allow testing 
of SpnMod10TE using a larger substrate, such as 11-undecynoyl-S-NAC. 
The stereochemical substrate selectivity of EryMod6TE is tantalizing. 
PikMod6TE’s ability to extend diketides of more than one stereoconfiguration suggests 
that combination of PikMod6TE with EryMod6TE into chimeric modules could test 
hypotheses about which domain is responsible for EryMod6TE’s substrate selectivity: the 
KS or the TE. Because recombination of two active constructs does not necessarily 
produce active constructs, multiple chimeras should be designed and assembled in 
parallel. Any construct designs should be mindful of ACP/KS interactions demonstrated 
in the DEBS system (Kapur et al. 2010). Two constructs should be designed for each 
crossover point, one with EryMod6TE for the N-terminal portion and one with 
PikMod6TE for the N-terminal portion. 
Although activity of a bimodular system has been measured in-lab using CoA-
based substrates and radio-TLC (Andrew Harper, unpublished results) integration of 
truncated extender units has not yet been achieved with a multimodular system. Activity 
of a multimodular system or even an entire synthase in a cell-free context would be a 




N-acetylcysteamine (NAC) (Hughes and Keatinge-Clay 2011) and all β-ketoacyl-
S-NAC substrates (2-4) (Piasecki et al. 2011) were synthesized according to literature 
procedures. Methylmalonic acid was purchased from TCI America, ATP was purchased 
from Meiya Pharmaceuticals, and NADP
+
 was purchased from CalBioChem. IPTG was 
purchased from either CarboSynth or Anatrace, and Ni-NTA agarose was purchased from 
Amintra. For purified proteins, final concentrations were determined using a Thermo 
Scientific Nanodrop 1000. Acrylamide for SDS-PAGE was purchased as a 30% 
acrylamide and bis-acrylamide solution (19:1) from BioRad and gels were poured 
according to the manufacturer’s instruction. Sonication was done using a Misonix S-4000 
ultrasonic processor set to 10 % amplitude with 0.5 inch horn and tip. All biocatalytic 
reactions were performed at ambient temperature (~23 °C). Thin layer chromatography 
(TLC) was conducted with EMD gel 60 F254 pre-coated plates (0.25 mM). TLCs were 
visualized with vanillin stain made by adding 1.5 mL 95-98% H2SO4 dropwise to 6 g 
vanillin dissolved in 95 mL ethanol. Fisher scientific silica gel 60 (particle size 230-400 
μm) was used for flash column chromatography. All HPLC monitoring was performed on 
a Waters 1525 binary HPLC pump connected to a Waters 2998 photodiode array detector 
using a Varian Microsorb-MV C18 column (250 x 4.6 mm, 5 μm particle size, 100 Å pore 
size) with a matching Metaguard column and mobile phases consisting of water with 
0.1% TFA (solvent A) and methanol with 0.1% TFA (solvent B) at a flow rate of 1 
mL/min. 
1
H NMR data were acquired on a Varian Mercury 400 MHz instrument at 
ambient temperature and are reported in terms of chemical shift (δ ppm), multiplicity, 
coupling constant, and integration and are referenced downfield from (CH3)4Si to the 
residual solvent peak at 7.26 ppm for CDCl3 as an internal standard. 
13
C NMR data were 
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acquired on either a Varian Mercury 400 MHz instrument or a Varian Oxford 600 MHz 
instrument at ambient temperature and are reported in terms of chemical shift and 
referenced to the residual solvent peak at 77.16 ppm for CDCl3 as an internal standard. 
LC-MS analysis was performed on an Agilent Technologies 1200 Series HPLC with a 
Gemini C18 column (5 μm, 2 x 50 mm, Phenomenex) coupled to an Agilent Technologies 
6130 quadrupole mass spectrometer system equipped with an electrospray-ionization 
source. A 5-95% B gradient over 12 minutes at a flow rate of 0.7 mL/min was run in 
which the mobile phases were water with 0.1% formic acid (solvent A) and acetonitrile 
with 0.1% formic acid (solvent B).  
CLONING 
Step number Temperature (°C) Duration (s)  
1. 98 60  
2. 98 5  
3. Primer specific 10  
4. 72 Template specific Go to step 5 (39 x) 
5. 72 300  
6. 4 Hold  
Table 2. Standard PCR thermal protocol. 
Step number Temperature (°C) Duration (s)  
1. 98 60  
2. 98 5  
3. 70 10 Decrease 2 °C each round 
4. 72 Template Specific Go to step 2 (9 x) 
5. 98 5  
6. Primer specific 10  
7. 72 Template specific Go to step 5 (29 x) 
8. 72 300  
9. 4 Hold  
Table 3. Touchdown PCR thermal protocol. 
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Unless otherwise noted, PCR reactions were 10ul and consisted of 1x Phusion GC 
buffer, 0.1 units of Phusion polymerase, 100 μM ea. dNTPs, 1ng/ul template DNA, and 1 
μM ea. forward and reverse primers. Thermocycling was done according to a standard 
(Table 2) or touchdown protocol (Table 3) with tailored annealing temperatures an 
extension times. Primers are detailed in Table 4 and were ordered from Sigma. All 
restriction enzymes and T4 ligase were purchased from New England Biolabs and used 
according to the manufacturer’s suggested protocols. Agarose gel purification was done 
using Qiagen’s QiaQuick kit. Plasmid DNA was purified using Qiagen’s QiaPrep kit. 
Sequencing was done at the University of Texas Institute for Cellular and Molecular 




Template  Sequence (5’ → 3’) 
Amp1 Forward 5’ CAAAAAGCATACAATCAACTATCAACTATTAAC 
TATATCGTAATACCATATGCCGGACGAAAGTAAGC
TCGTCGA 3’ 
 Reverse 5’ CGGCCGGCAGGTCCCGCAT 3’ 
Amp2 Forward 5’ ACTGTCCCTGGAGGACGCCTGCA 3’ 
 Reverse 5’ GTCGAGGTCGACGAGCAGCAGGCT 3’ 
Amp3 Forward 5’ CCTCGACGACGAGGACGTCCTGGA 3’ 
 Reverse 5’ CGCACAAATTTGTCATTTAAATTAGTGATGGTGA 
TGGTGATGCACGTGAAGCTTGGCCTCGCCGGCCGG
AAGTTC 3’ 
OleMod6TE Forward 5’ GTGACGTGTCATATGCTCGCCGCCTCCCGTGAAG 
CGATC 3’ 
 Reverse 5’ GAGACTTAGCTCGAGGGGGGTGAGCCCCTTCAG 
CCAGACGT 3’ 
PikMod6TE Forward 5’ AAAGGGAGCCATATGACGAGTTCCAACGAACAG 
TTGGTGGAC 3’ 
 Reverse 5’ GTCCGGATTCTCGAGCTTGCCCGCCCCCTCGATG 
CCCTCGA 3’ 
SpnMod10TE Forward 5’ GAGTAGATACATATGCCGGTCGCCGAAGACGAT 
CTCGTCGCGA 3’ 
 Reverse 5’ TAAAGCCAACTCGAGGCGTTGCCGAGCGGTGCG 
CTGGTTGAGTTTGTCA 3’ 
TylMod7TE Forward 5’ AATCGCATGCATATGATGGCCATGTCCGCCGA 3’ 
 Reverse 5’ GCTGTTAGAAAGCTTGCGGCCTCTCCTCTCTCCC 
C 3’ 
Table 4. Primer sequences. 
AmpMod18TE  
A condition to amplify AmpMod18TE as a single fragment was not found. 
Instead it was amplified in three smaller fragments: Amp1, Amp2, and Amp3. Each 
fragment has ~50-100bp of sequence overlap with each other and the vector XW55 
(Darren Gay, unpublished data). This will allow for homologous recombination in 
Saccharomyces cerevisiae of all three gel-purified fragments and XW55 that has been 
digested with NdeI and PmlI. All three fragments were amplified from Streptomyces 
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nodosus genomic DNA using the standard thermal profile (Table 2) with a 74.5 °C 
annealing temperature, a 40s extension time, and 5% v/v DMSO. Amplification of Amp2 
was somewhat weak and may benefit from increased DMSO concentration. Once 
assembled in S. cerevisiae, AmpMod18TE may be moved into pET28b by the use of 
NdeI and HindIII cut sites. 
OleMod6TE 
OleMod6TE was amplified from Streptomyces antibioticus genomic DNA using 
the standard thermal profile (Table 2) with a 74.5 °C annealing temperature, a 120 s 
extension time, and 6% DMSO. Primers included NdeI and XhoI cut sites for insertion 
into pET28b. 
PikMod6TE 
PikMod6TE was amplified from Streptomyces venezuelae genomic DNA using 
the touchdown thermal profile (Table 3) with a 64 °C annealing temperature, a 120 s 
extension time, and 5% DMSO. Gel purified amplicon and pET28b were digested with 
NdeI and XhoI and the vector was subsequently treated with alkaline phosphatase. 
Ligation and successful transformation were confirmed with Sanger sequencing. 
SpnMod10TE 
SpnMod10TE was amplified from Saccharopolyspora spinosa genomic DNA 
using the standard thermal profile (Table 2) with a 71.4 °C annealing temperature, a 120 s 
extension time, and 4% DMSO. Gel purified amplicon and pET28b were digested with 
NdeI and XhoI and the vector was subsequently treated with alkaline phosphatase. 
Ligation and successful transformation were confirmed with Sanger sequencing. 
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TylMod7TE 
TylMod7TE was amplified from Streptomyces fradiae genomic DNA using the 
standard thermal profile (Table 2) with a 74.5°C annealing temperature, a 120 s extension 
time, and 6% DMSO. Primers included NdeI and HindIII cut sites for insertion into 
pET28b. 
PROTEIN EXPRESSION AND PURIFICATION  
Streptomyces coelicolor MatB, (Hughes and Keatinge-Clay 2011) TylKR1, 
EryKR1, AmpKR, MycKR5, GDH (Piasecki et al. 2011), and RifKR7 (Valenzeno et al. 
2010) were expressed in E. coli BL21 (DE3). All PKS constructs were expressed in E. 
coli K207-3 (Murli et al. 2003). Starter cultures (50 mL) were grown to inoculate pre-
warmed Luria broth supplemented with 25 mg/mL kanamycin. When OD600 reached 0.4, 
the media was cooled to 15 °C and then induced with 0.5 mM IPTG. After 16 h, the cells 
were harvested by centrifugation (3,000 x g for 20 minutes), and the pellets of 6 L of cell 
growth were resuspended in 50 mL lysis buffer (30 mM HEPES pH 7.5, 250 mM NaCl, 
10 % v/v glycerol). In lysis buffer for SpnMod10TE, NaCl concentration was raised to 
500 mM and glycerol concentration was raised to 20% v/v. The cells were then lysed by 
sonication on ice with two rounds of 15 separate 2 s pulses with 10 s between pulses and 
60 s between rounds. Cellular debris was then removed by centrifugation (30,000 x g for 
45 minutes). For proteins that were purified (MatB and GDH), the crude lysate was 
passed over a nickel-NTA column equilibrated with lysis buffer. The column was washed 
with lysis buffer containing 15 mM imidazole, and the protein was eluted with lysis 
buffer containing 150 mM imidazole. For isolated ketoreductases (EryKR1, TylKR1, 
AmpKR2, and RifKR7) and PKSs, lysate was used. To generate lysate, cells from 6 L of 
cell growth were pelleted after expression (3,000 x g for 20 minutes), and the pellets of 
were resuspended in 50 mL lysis buffer before sonication (using the protocol above) and 
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centrifugation (30,000 x g for 45 minutes). The crude lysate was then twice dialyzed for 8 
h at 4 °C in 10 kDa MWCO cellophane dialysis tubing against 1 L of lysis buffer.  
BIOCATALYTIC SYNTHESES 
Extender units (MatB reaction) 
 Reactions generating methylmalonyl-S-NAC (1) contained 500 mM HEPES (pH 
8.0), 100 mM NaCl, 10 % v/v glycerol, 100 mM sodium methylmalonate, 100 mM ATP, 
200 mM MgCl2, 100 mM NAC, and 0.5 mg/mL MatB and were allowed to proceed at for 
48 h before immediate use or storage at 4 °C. Reaction progress was monitored via 
HPLC at 235 nm (linear gradient of 0-50% B over 15 minutes) (Hughes and Keatinge-
Clay 2011). To generate malonyl-S-NAC, sodium malonate was substituted for sodium 
methylmalonate.  
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β-hydroxyacyl-S-NACs (KR reactions) 
 
Figure 11. KR types used to generate β-hydroxy-diketide-S-NACs. 
Generation of reduced diketides was performed in 500 mM HEPES (pH 7.5), 100 
mM NaCl, 15% v/v glycerol, 5% v/v DMSO, 300 mM D-glucose, 1 mM NADP
+
, 100 
mM β-ketoacyl-S-NAC 2-4, 0.05 mg/mL GDH, and 20% v/v KR-containing lysate and 
went to completion after 16 h. Use of TylKR1 generated 6 and 7 from 3 and 4, 
respectively. To generate 5 and its three stereoisomers, a KR of each type (Keatinge-Clay 
2007) was used to generate its cognate reduced diketide-S-NAC product from 2 (Piasecki 
et al. 2011): The A1-type AmpKR2 for the (2R,3S)-diketide, A2-type RifKR7 
(Valenzeno et al. 2010) for the (2S,3S)-diketide, the B1-type TylKR1 for the (2R,3R)-
diketide, and the B2-type EryKR1 for the (2S,3R)-diketide (5) (Figure 11). Reaction 
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progress was monitored by TLC (15% MeOH:CHCl3) and HPLC absorbance at 235 nm 
(linear gradient of 15-35% B over 20 minutes). 
Triketide lactones from EryMod6TE 
The progress of reactions yielding triketide lactones 8-13 was monitored via TLC 
(50% EtOAc:hexanes) and vanillin staining. For 0.5 mmol reactions yielding β-hydroxy 
triketide lactones 8, 9, or 10, 5 mL of MatB reaction yielding methylmalonyl-S-NAC 1 
and 5 mL of KR reaction yielding 5, 6, or 7 (respectively) were combined with 20 mL of 
EryMod6TE lysate. After 24 h, the reactions were extracted with EtOAc (3 x 150 mL), 
dried with MgSO4, filtered, and concentrated under vacuum. This crude extract was then 
extracted with 100 mL of chloroform to remove remaining glycerol, concentrated under 
vacuum, and purified by flash chromatography (70% EtOAc:hexanes). 
To produce ketolactones 11, 12, or 13, the same procedure was used with the 
following amendment: 5 mL of the same KR reaction was first extracted with EtOAc (3 x 
50 mL), dried with MgSO4, filtered, and concentrated under vacuum, and resuspended in 
5 mL of 500mM HEPES pH 7.5. It was then combined with 5 mL of MatB reaction and 
20 mL of EryMod6TE lysate as before.  
The preparative (7 mmol) reaction of 10 was done by combining 70 mL of MatB 
reaction with 70 mL of KR reaction containing 7 and 190 mL of EryMod6TE lysate. 
After two days the reaction was extracted with EtOAc (6 x 250 mL). The remaining 
emulsion was centrifuged (1000 x g for 1 minute) and the organic phase was removed. 
The remaining aqueous phase was then extracted with EtOAc (2 x 250 mL), and the 
remaining emulsion was centrifuged again (1000 x g for 1 minute) and the organic phase 
was again removed. The combined organic phases were dried with MgSO4, filtered, and 
concentrated under vacuum. The crude extract was then extracted with chloroform (2 x 
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200 mL) to remove remaining glycerol, concentrated under vacuum,  and purified via 
flash column chromatography (silica, 50% EtOAc:hexanes). 
NMR characterization of triketide lactones 
(2R,3S,4S,5R)-3,5-Dihydroxy-2,4-dimethylheptanoic acid δ-lactone (8). 
1
H NMR 
(400 MHz, CDCl3) δ= 4.13 (m, 1H), 3.82 (dd, J=4.5 Hz, J=10 Hz, 1H), 2.47 (dq, J=4.5 
Hz, 7 Hz, 1H), 2.17 (m, 1H), 1.83 (m, 1H), 1.55 (m, 1H), 1.41 (d, J=7 Hz, 3H), 1.00 (t, 
J=7 Hz, 3H), 0.97 (d, J=7 Hz,3H). 
13
C NMR (600 MHz, CDCl3) δ=173.51, 81.31, 73.96, 
39.84, 36.75, 25.26, 14.26, 9.86, 4.35. This characterization is in agreement with 
literature reported data (Kao et al. 1994). 
(2R, 3S, 5R)-3,5-Dihydroxy-2-methylheptanoic acid δ-lactone (9). 
1
H NMR (400 
MHz, CDCl3) δ= 4.16 (m, 1H), 3.76 (td, 10.5, 4.5 1H), 2.35 (m, 1H), 2.20 (m, 1H), 1.82-
1.62 (m, 3H), 1.41 (d, J=7 Hz, 3H), 1.00 (t, J=7 Hz, 3H). 
13
C NMR (400 MHz, CDCl3) 
173.53, 77.89, 70.48, 45.24, 37.84, 28.94, 13.63, 9.29. 
(2R, 3S, 5R)-3,5-Dihydroxy-2-methyloctanoic acid δ-lactone (10). 
1
H NMR (400 
MHz, CDCl3) δ= 4.24 (m, 1H), 3.76 (m, 1H), 2.35 (m, 1H), 2.20 (m, 1H), 1.78-1.46 (m, 
5H), 1.40 (d, J=7 Hz, 3H), 0.92 (t, J=7 Hz, 3H). 
13
C NMR (400 MHz, CDCl3). δ= 
174.06, 76.70, 70.15, 45.15, 38.26,38.01, 18.12, 13.87, 13.62.  
(4S, 5R)-2,4-Dimethyl-3-oxoheptanoic acid δ-lactone (11). 
1
H NMR (400 MHz, 
CDCl3) δ= 4.65 (m, 1H), 3.61 (q, J=7 Hz, 1H), 2.62 (dq, J=7 Hz, J=3.2 Hz, 1H), 1.85 (m, 
1H), 1.65 (m, 1H), 1.36 (d, J=7 Hz, 3H), 1.12 (d, J=7 Hz, 3H), 1.07 (t, J=7 Hz, 3H). 
13
C 
NMR (400 MHz, CDCl3) δ= 205.59, 170.23, 78.68, 50.55, 44.52, 24.18, 10.07, 9.88, 
8.39.  NMR shifts suggest that 11 is a keto tautomer in solution, although it crystalized as 
the enol tautomer (Figure 5). 
 33 
(5R)-2-Methyl-3-oxoheptanoic acid δ-lactone (12). 
1
H NMR (400 MHz, CDCl3) 
δ= 4.64 (m, 1H), 3.57 (q, J=6.5 Hz, 1H), 2.74 (dd, J=2.8 Hz, J=19 Hz, 1H), 2.44 (dd, 
J=12 Hz, J=19 Hz, 1H), 1.90-1.75 (m, 2H), 1.37 (d, J=6.5 Hz, 3H), 1.08 (t, J=7 Hz, 3H). 
13
C NMR (400 mHz, CDCl3) δ= 201.71, 170.07, 75.46, 51.80, 42.83, 27.65, 9.33, 7.93. 
(5R)-2-Methyl-3-oxooctanoic acid δ-lactone (13). 
1
H NMR (400 MHz, CDCl3) 
δ= 4.70 (m, 1H), 3.56 (q, J=6.5 Hz, 1H), 2.73 (dd, J=2.7 Hz, J=19 Hz, 1H), 2.47 (dd, 
J=12 Hz, J=18 Hz, 1H), 1.6-1.4 (m, 3H), 1.36 (d, J=6.5 Hz, 3H), 0.99 (t, J=7 Hz, 3H). 
13
C 
NMR (400 MHz, CDCl3) δ=201.76, 170.13, 74.04, 51.82, 43.22, 36.47, 18.16, 13.79, 
7.83. 
MONITORING OF KETOLACTONE FORMATION BY HPLC 
EryMod6TE time courses with B-type and B2-type products 
MatB reaction and extracted, reduced diketide were prepared and HPLC-analyzed 
as indicated above. Ketolactone reactions consisted of 250 μL MatB reaction, 1 mL PKS 
lysate, an amount of extracted β-hydroxyacyl-S-NAC equivalent to that of 
methylmalonyl-S-NAC (as estimated by HPLC peak area), and 500 mM HEPES pH 7.5 
added to produce a final volume of 2.1 mL. Timepoints were taken at 0, 1, 2, 4, 8, 12, 22, 
and 24 h by quenching 200 μL of the reaction with an equal volume of 2 M acetic acid in 
methanol and storing at -20 °C until analyzed. Before analysis, timepoint samples were 
centrifuged at 21,000 x g for 1 min (to pellet precipitate) and the supernatant was filtered 
through a 0.45 μm nylon membrane. For reactions yielding 11-13, 20-minute linear 
gradients (5-100% solvent B) were performed. For reactions yielding 12, an additional 
isocratic run (30% B) was necessary to separate 6 from 12. 25 μL of the quenched 
reaction was injected for each timepoint and absorbance was monitored at 242 nm 
(Figures 6-9). Ketolactone formation was further confirmed via LC-MS (Table 5). 
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Compound Formula m/z (expected) m/z (observed) 
11 C9H14O3 171.09 171.4 
12 C8H12O3 157.08 157.2 
13 C9H14O3 171.09 171.2 
Table 5. LC/ESI-MS confirming ketolactone formation. 
Stereochemical substrate selectivity of EryMod6TE and PikMod6TE 
The reactions to form 5 and its stereoisomers were performed, extracted, and 
analyzed using the procedure detailed above. Generation of 1 was also performed using 
the conditions described above. Ketolactone reactions consisted of 250 μL MatB reaction, 
1 mL PKS lysate, an amount of extracted β-hydroxyacyl-S-NAC equivalent to that of 
methylmalonyl-S-NAC (as estimated by HPLC peak area), and 500 mM HEPES pH 7.5 
added to produce a final volume of 2.1 mL. Timepoints taken at 0, 4, and 22 h were 
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